-+ 0.00%
-+ 0.00%
-+ 0.00%

Entrada reports positive Phase 1/2 Cohort 1 data for Duchenne drug ENTR-601-44

PUBT·05/07/2026 11:18:06
Listen to the news
Entrada reports positive Phase 1/2 Cohort 1 data for Duchenne drug ENTR-601-44
  • Entrada Therapeutics reported positive topline results from Cohort 1 of Phase 1/2 ELEVATE-44-201 testing ENTR-601-44 in ambulatory Duchenne muscular dystrophy patients with mutations amenable to exon 44 skipping.
  • Readout showed favorable safety and tolerability with no serious adverse events or discontinuations, supporting continued dose escalation in study.
  • Treated participants showed early functional improvement versus placebo, despite lower-than-expected drug exposure in pediatric patients versus healthy adults.
  • Dosing has started in Cohort 2 at higher dose, with additional results from Cohort 1 open-label extension and Cohort 2 expected by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.